Disease relevance of Protein-Losing Enteropathies

• Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal alpha 1-antitrypsin [1].
• Pure red cell aplasia and protein-losing enteropathy in a patient with systemic lupus erythematosus [2].
• CONCLUSION: Increased gastro-intestinal protein loss is common in this select group of late survivors of Fontan surgery and in other subjects with congenital heart disease and chronic elevation of systemic venous pressure, and was present in patients who did not have protein-losing enteropathy [3].
• Phosphomannose isomerase deficiency as a cause of congenital hepatic fibrosis and protein-losing enteropathy [4].
• Fecal alpha 1-antitrypsin excretion, a noninvasive indicator of protein-losing enteropathy, was correlated with clinical disease activity in pediatric patients with Crohn's disease [5].

High impact information on Protein-Losing Enteropathies

• Systemic lupus erythematosus with a protein-losing enteropathy [6].
• Octreotide for protein-losing enteropathy with intestinal lymphangiectasia [7].
• An intestinal clearance test of alpha 1-antitrypsin revealed the association of protein-losing enteropathy [8].
• The use of parenteral nutrition is advocated in severe cases with exudative enteropathy [9].
• Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy [10].

Chemical compound and disease context of Protein-Losing Enteropathies

• Of the 15 subjects who were found to have increased gastro-intestinal protein loss, only four had clinical protein-losing enteropathy [3].
• Segmental small intestinal allografts. II. Inadequate function with cyclosporine immunosuppression: evidence of a protein-losing enteropathy [11].
• Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation [12].
• Technetium-99m dextran: a promising new protein-losing enteropathy imaging agent [13].
• Detection and quantification of protein-losing enteropathy with indium-111 transferrin [14].

Anatomical context of Protein-Losing Enteropathies

• We studied three pediatric patients with protein-losing enteropathy in conjunction with univentricular hearts and right atrial to pulmonary artery anastomosis (Fontan operation) before and during heparin therapy [12].
• Measurement of alpha 1-antitrypsin in feces has been proposed as a method of diagnosing a protein-losing enteropathy [15].
• Two dogs were emaciated and hypoalbuminemic due to protein-losing enteropathy associated with a severe, focal, mucoid, cryptal ectasia of the duodenum and marked villus atrophy [16].
• Although partial regression of protein-losing enteropathy was obtained with high doses of cortisone, complete resolution of the phenomenon was accomplished only after surgical closure of a left-to-right shunt through the pulmonary valve [17].
• The small intestinal exudates of patients with protein-losing enteropathies produced by celiac disease or proximal jejunal Crohn's disease were compared with controls [18].

Gene context of Protein-Losing Enteropathies

• Laboratory tests for fecal alpha 1-antitrypsin and an indium III-labeled plasma transferrin nuclear scan revealed a protein-losing enteropathy [19].
• Combination therapy with a somatostatin analogue and corticosteroid may be effective for protein losing enteropathy with intractable diarrhea ascribable to GI amyloidosis [20].
• Faecal excretion of alpha 1-antitrypsin in protein-losing enteropathy [21].
• Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy [22].
• Inferior vena cava occlusion and protein-losing enteropathy after liver transplantation in children [23].

Analytical, diagnostic and therapeutic context of Protein-Losing Enteropathies

• Their protein losing enteropathies subsided after treatment with 60 mg/day oral prednisolone [24].

References